The WSJ reports, Novo Nordisk said the European Unions drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes
2 Will more people qualify for Wegovy on the NHS soon
The Obesity Epidemic For years in the US, weve been hearing about the growing obesity epidemic
Researchers considering extended protocols should be aware that this safety gap exists and should monitor for unexpected effects in tissues where NNMT has normal physiological functions
Use of this medicine may cause nausea, diarrhea, vomiting, dizziness, and hypotension
This characteristic may be beneficial for individuals seeking to increase caloric intake (such as in clinical wasting scenarios) but is often unwanted in body composition optimization protocols